Multiple Sclerosis Home > Rebif and Breastfeeding
Before starting Rebif (interferon beta-1a), breastfeeding women should consult their healthcare providers about the benefits and possible risks. Currently, it is not known whether the drug passes through breast milk. However, since Rebif is a delicate molecule that can be destroyed by the digestive system, it would probably be destroyed by an infant's digestive system if it passes through breast milk.
Rebif® (interferon beta-1a) is a prescription multiple sclerosis treatment. It belongs to a group of medications known as interferons. Because the risks of using Rebif while breastfeeding are not currently known, the manufacturer recommends that it be used with caution in breastfeeding women. Therefore, be sure to talk with your healthcare provider if you take Rebif and are breastfeeding or are thinking of starting.
No studies have been conducted on whether Rebif passes through breast milk. However, the drug is a delicate molecule that cannot be taken by mouth. Instead, it must be taken by injection, since the digestive system would destroy the molecule. Therefore, even if Rebif passes through breast milk, it would be destroyed and inactivated by the infant's digestive system. However, since no studies have been performed, it is impossible to predict exactly what effects Rebif may cause in a breastfed infant.
You and your healthcare provider must consider the benefits of Rebif to you, the benefits of breastfeeding for your baby, and the possible unknown risks of Rebif to your baby in your particular situation.
You should talk with your healthcare provider about Rebif and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision about Rebif and breastfeeding that is right for you.